Kezar Life Sciences, Inc. was acquired by Aurinia Pharma U.S., Inc. on May 11, 2026, according to the Form 8-K Kezar Life Sciences, Inc. filed with the SEC. It is the only completed acquisition Aurinia Pharma U.S., Inc. reported under Item 2.01 in the last twelve months (Form 8-K, May 11, 2026).
1 companies announced an acquisition this week.
Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.
| Bowman Consulting Group Ltd. | agreed to be acquired by Prive Parent, Inc. |
Competing with, selling to or investing in Aurinia Pharma U.S., Inc. after this deal? See the free Snapshot first.
Free to see. No signup.
Aurinia Pharma U.S., Inc. completed its acquisition of Kezar Life Sciences, Inc. on 2026-05-11, according to the Form 8-K Kezar Life Sciences, Inc. filed with the SEC on 2026-05-11. The filing's Item 2.01 states no aggregate dollar price. Kezar Life Sciences, Inc. filed the report because the deal made it part of Aurinia Pharma U.S., Inc..
| Acquirer | Aurinia Pharma U.S., Inc. |
|---|---|
| Acquired | Kezar Life Sciences, Inc. |
| Completed | 2026-05-11 |
| Reported by | Kezar Life Sciences, Inc. (KZR), the company acquired |
| Filing | Form 8-K, filed 2026-05-11 |
Want the whole picture on Aurinia Pharma U.S., Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aurinia Pharma U.S., Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aurinia Pharma U.S., Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On May 11, 2026, Merger Sub merged with and into the Company (the " Merger "), pursuant to which the separate corporate existence of Merger Sub ceased and the Company continued as the surviving corporation in the Merger (the " Surviving Corporation ") and a wholly owned subsidiary of Parent.
More from the filing
As previously disclosed by Kezar Life Sciences, Inc. (the " Company ") in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the " SEC ") on March 30, 2026, the Company entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Aurinia Pharma U.S., Inc., a Delaware corporation (" Parent " or " Aurinia "), Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Merger Sub " and together with Parent, the " Buyer Entities "), and, solely for purposes of Section 10.13 of the Merger Agreement, Aurinia Pharmaceutica
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on May 11, 2026, Parent completed a tender offer to purchase all of the Company's outstanding shares (the " Shares ") of common stock, par value $0.001 per share, in exchange for (i) $6.955 per Share, payable in cash, without interest (such amount, or any different amount per Share paid pursuant to the Offer, the " Cash Amount "), plus (ii) one contingent value right per Share (each, a " CVR "), which represents the right to receive certain payments in cash in accordance with the terms and subject to th
The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m.
Quoted from Kezar Life Sciences, Inc.'s Form 8-K.
This is the only completed acquisition Aurinia Pharma U.S., Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Aurinia Pharma U.S., Inc.Look up Aurinia Pharma U.S., Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Aurinia Pharma U.S., Inc.Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.